Meta-analysis of<sup>18</sup>fluorodeoxyglucose positron emission tomography-CT for diagnosis of lung malignancies in patients with head and neck squamous cell carcinomas

Xi, Kai; Xie, Xiaojuan; Xi, Shoumin

doi:10.1002/hed.23774

Cited by 10 publications

(10 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 Traditional white light endoscopy (WLE) can detect morphologic changes in the superficial mucosa, and it is widely used in the diagnosis of NPC. 5,6 However, for some NPCs in the early stage, the superficial tumor zone is difficult to identify or differentiate from other pathologies, such as lymphoid follicular hyperplasia. Therefore, it is of primary importance to establish a more useful screening protocol for NPC diagnosis and to administer treatment in the early stages of disease.…”

mentioning

confidence: 99%

Diagnostic Performance of Narrow Band Imaging for Nasopharyngeal Cancer: A Systematic Review and Meta‐analysis

Sun

Zhang

Han

et al. 2018

Otolaryngol.--head neck surg.

View full text Add to dashboard Cite

Objective The purposes of this study were to verify the effectiveness of the narrow band imaging (NBI) system in diagnosing nasopharyngeal cancer (NPC) as compared with white light endoscopy. Data Sources PubMed, Cochrane Library, EMBASE, CNKI, and Wan Fang databases. Review Methods Data analyses were performed with Meta-Disc. The updated Quality Assessment of Diagnostic Accuracy Studies-2 tool was used to assess study quality and potential bias. Publication bias was assessed with a Deeks asymmetry test. The registry number of the protocol published on PROSPERO is CRD42015026244. Results This meta-analysis included 10 studies of 1337 lesions. For NBI diagnosis of NPC, the pooled values were as follows: sensitivity, 0.83 (95% CI, 0.80-0.86); specificity, 0.91 (95% CI, 0.89-0.93); positive likelihood ratio, 8.82 (95% CI, 5.12-15.21); negative likelihood ratio, 0.18 (95% CI, 0.12-0.27); and diagnostic odds ratio, 65.73 (95% CI, 36.74-117.60). The area under the curve was 0.9549. For white light endoscopy in diagnosing NPC, the pooled values were as follows: sensitivity, 0.79 (95% CI, 0.75-0.83); specificity, 0.87 (95% CI, 0.84-0.90); positive likelihood ratio, 5.02 (95% CI, 1.99-12.65); negative likelihood ratio, 0.34 (95% CI, 0.24-0.49); and diagnostic odds ratio, 16.89 (95% CI, 5.98-47.66). The area under the curve was 0.8627. The evaluation of heterogeneity, calculated per the diagnostic odds ratio, gave an I of 0.326. No marked publication bias ( P = .68) existed in this meta-analysis. Conclusion The sensitivity and specificity of NBI for the diagnosis of NPC are similar to those of white light endoscopy, and the potential value of NBI for the diagnosis of NPC needs to be validated further.

show abstract

mentioning

confidence: 99%

Diagnostic Performance of Narrow Band Imaging for Nasopharyngeal Cancer: A Systematic Review and Meta‐analysis

Sun

Zhang

Han

et al. 2018

Otolaryngol.--head neck surg.

View full text Add to dashboard Cite

show abstract

“…Most PET/CTs are interpreted in a qualitative manner, which is a risk factor for subjective interpretation. 20 Different scanning parameters, such as patient preparation, blood glucose level, timing of imaging taken, and FDG dose, have also been shown to affect the accuracy of PET/CT. 20 In assessing the lungs, granulomatous, infective, and inflammatory processes of the lung can increase uptake of 18 FDG, mimicking malignant nodules.…”

Section: Discussionmentioning

confidence: 99%

Workup of Suspected Chest Metastases on ¹⁸F-FDG-PET/CT in Head and Neck Cancer: Worth the Wait?

et al. 2019

View full text Add to dashboard Cite

The objective of our study is to assess the impact of equivocal or positive positron emission tomography combined with low-dose noncontrast computed tomography (PET/CT) findings in the chest on treatment for head and neck cancer (HNC). We reviewed charts of patients presented at Augusta University’s Head and Neck Tumor Board (AUTB) between 2013 and 2016 with the following exclusion criteria: <18 years, Veterans Affairs patients, those with incomplete data, and those without a history of head and neck squamous cell carcinoma. The lung/thorax sections of the radiologists’ PET/CT reports were graded as “Positive, Equivocal, or Negative” for chest metastases. Patients who underwent workup for suspected chest metastases were assessed for treatment delays, changes in treatment plans, and complications. In addition, we evaluated the time between AUTB presentation and peri-treatment PET/CT to primary treatment initiation were calculated between groups. There was a total of 363 patients with PET/CT prior to treatment, the read was “Negative” in 71.3% (n = 259), “Equivocal” in 20.9% (n = 76), and “Positive” in 5.8% (n = 21). Of 272 patients with complete treatment data, 22 underwent workup for suspected chest metastases. Mean time from PET/CT to treatment initiation was 27.5 days without workup and 64.9 days with workup ( P < .0001), and from AUTB presentation was 29.1 days without workup and 62.5 days with workup ( P < .0001). Five (19.2%) patients experienced a complication from workup. Twenty (76.9%) patients had no changes in their treatment plan after workup. In conclusion, our results for potential chest metastases on PET/CT in patients with HNC are often not clear-cut. Workup of suspected chest metastasis based on PET/CT findings significantly delays primary treatment initiation and may cause serious complications.

show abstract

“…On the other hand, the excellent diagnostic performance of 18 F-FDG PET/CT for detecting distant metastases is clearly underlined in the literature [24][25][26][27][28][29]. Xu et al showed a pooled sensitivity and specificity of 85.7% and 98.1%, respectively, for 18 F-FDG PET/CT, resulting in a significantly better M staging than CI [26].…”

Section: Nodal and Distant Metastases Detectionmentioning

confidence: 99%

“…On the other hand, for detection of liver metastases 18 F-FDG PET/CT requires further optimization and integration with CI, especially contrast-enhanced CT and MRI [25]. About lung metastases, a metaanalysis demonstrated that 18 F-FDG PET/CT is a valuable diagnostic tool for diagnosing lung malignancies in patients with HNSCC [29].…”

Section: Nodal and Distant Metastases Detectionmentioning

confidence: 99%

Evidence-Based PET for Head and Neck Tumours

Paone

2020

Evidence-Based Positron Emission Tomography

View full text Add to dashboard Cite

Meta-analysis of¹⁸fluorodeoxyglucose positron emission tomography-CT for diagnosis of lung malignancies in patients with head and neck squamous cell carcinomas

Abstract: (18) FDG PET-CT is a valuable diagnostic tool for diagnosing lung malignancies in patients with HNSCC.

Cited by 10 publications

References 23 publications

Diagnostic Performance of Narrow Band Imaging for Nasopharyngeal Cancer: A Systematic Review and Meta‐analysis

Diagnostic Performance of Narrow Band Imaging for Nasopharyngeal Cancer: A Systematic Review and Meta‐analysis

Workup of Suspected Chest Metastases on ¹⁸F-FDG-PET/CT in Head and Neck Cancer: Worth the Wait?

Evidence-Based PET for Head and Neck Tumours

Contact Info

Product

Resources

About

Meta-analysis of18fluorodeoxyglucose positron emission tomography-CT for diagnosis of lung malignancies in patients with head and neck squamous cell carcinomas

Abstract: (18) FDG PET-CT is a valuable diagnostic tool for diagnosing lung malignancies in patients with HNSCC.

Cited by 10 publications

References 23 publications

Diagnostic Performance of Narrow Band Imaging for Nasopharyngeal Cancer: A Systematic Review and Meta‐analysis

Diagnostic Performance of Narrow Band Imaging for Nasopharyngeal Cancer: A Systematic Review and Meta‐analysis

Workup of Suspected Chest Metastases on 18F-FDG-PET/CT in Head and Neck Cancer: Worth the Wait?

Evidence-Based PET for Head and Neck Tumours

Contact Info

Product

Resources

About

Meta-analysis of¹⁸fluorodeoxyglucose positron emission tomography-CT for diagnosis of lung malignancies in patients with head and neck squamous cell carcinomas

Workup of Suspected Chest Metastases on ¹⁸F-FDG-PET/CT in Head and Neck Cancer: Worth the Wait?